• The inaugural US E-Cigarette Summit was held in Washington DC, on Monday May 8, 2017 and welcomed over 250 people
  • The 2nd Annual US E-Cigarette Summit will take place April 30, 2018......Registration is now open

David Graham

President & Managing Partner
Reveritas Group

David Graham is President and Managing Partner of Reveritas Group, a multi-partner regulatory, clinical, and scientific consulting firm supporting ENDS companies in their efforts to comply with FDA regulations, with a current focus on plan development and execution of programs for Premarket Tobacco Applications (PMTA) to FDA. He also has a leadership role at GoodCat Laboratories, an ISO 17025 ALA accredited analytical test laboratory and OEM manufacturer of e-liquid for multiple ENDS companies, where he is overseeing the upscale of its production and analytical testing to meet demand for quality focused e-liquid and aerosol testing services. David also supports continuing program work on a National Institute of Drug Abuse (NIDA)-funded Small Business Innovation Research (SBIR) award to NJOY to develop a standardized research ENDS product for use for clinical research to evaluate ENDS for smoking cessation and risk reduction. (Currently the subject of a NIDA Funding Opportunity Announcement (FOA) that aims to evaluate ENDS effects on multiple behavioral and health biomarkers in current tobacco smokers and inform e-cigarette public health policy decision-making.)

David has unparalleled experience in nicotine related new product development, tobacco control policy, and related regulation in the healthcare and electronic nicotine delivery sectors spanning ~ 25 years. Beginning his work related to ENDS in 2013, David joined NJOY to lead the regulatory affairs, quality & compliance function for the company to develop its regulatory strategy and prepare for regulation, where he created and managed submissions related to FDA regulatory rule-making consultations, supported new product planning and development, and coordinated multiple meetings with FDA’s Office of the Director and Office of Science as well as other government agencies in the US and abroad. Previously, at Johnson & Johnson, Pfizer, and Pharmacia, David was instrumental in securing support and regulatory approval for new nicotine replacement therapy (NRT) products, access channels, and expanded indications in multiple countries, where he held various Vice President and Senior Director roles directing global public policy, tobacco dependence category and product development, and marketing for the Nicorette brand internationally. During this time David jointly established multiple ground-breaking public private partnerships with national governments, NGOs, and intergovernmental organizations including the World Health Organization in efforts to reduce the death and disease caused by smoking.

David is a graduate of Columbia University with a Master of Public Policy & Administration (MPA).

David Graham will be speaking at:

Addressing the Challenge of ENDS Regulation

- 14:20 - 14:35

Open Floor Q&A and Moderated Discussion

- 14:50 - 15:15

« Back to previous page